MURINE MONOCLONAL ANTIBODY HD 37/DG RICIN A CHAIN FOR LYMPHOMA

鼠单克隆抗体 HD 37/DG 蓖麻毒素 A 链治疗淋巴瘤

• 批准号: 3783498
• 负责人: ALBERT F LO BUGLIO
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3783498
• 关键词: clinical trials; dosage; human subject; human therapy evaluation; lymph nodes; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radionuclide therapy; nonHodgkin's lymphoma; pharmacokinetics

This phase I trial of HD37-SMPT-dgA in patients with chemotherapy resistant or relapsed B-cell non-Hodgkin's lymphoma will examine a novel schedule of administration & analysis to include pharmacokinetics, radioimmune localization at lymph node tumor sites & immunogenicity. The study will establish maximal tolerated dose & a dose/schedule to move to phase II trial status.

HD37-SMPT-dgA 在化疗耐药患者中的 I 期试验 或复发的 B 细胞非霍奇金淋巴瘤将检查新的时间表 给药和分析，包括药代动力学、放射免疫 淋巴结肿瘤部位的定位和免疫原性。 该研究将 确定最大耐受剂量和进入 II 期的剂量/时间表 试用状态。